WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

Search

Macerich Co-The

Închisă

SectorImobiliare

18.41 1.54

Rezumat

Modificarea prețului

24h

Curent

Minim

18.13

Maxim

19.05

Indicatori cheie

By Trading Economics

Venit

71M

-19M

Vânzări

9.8M

263M

Randament dividend

3.67

Marjă de profit

-7.132

Angajați

596

EBITDA

29M

168M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+9.82% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.67%

6.64%

Următoarele câștiguri

11 mai 2026

Data viitoare de dividende

30 mar. 2026

Următoarea dată ex-dividende

2 iun. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

134M

5.1B

Deschiderea anterioară

16.87

Închiderea anterioară

18.41

Sentimentul știrilor

By Acuity

59%

41%

125 / 167 Clasament în Real estate

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Macerich Co-The Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Macerich Co-The Așteptări

Obiectiv de preț

By TipRanks

9.82% sus

Prognoză pe 12 luni

Medie 19.9 USD  9.82%

Maxim 23 USD

Minim 17 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMacerich Co-The - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

11 ratings

4

Cumpărare

5

Păstrare

2

Vânzare

Scor tehnic

By Trading Central

14.67 / 15.08Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

125 / 167 Clasament în Imobiliare

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Macerich Co-The

Macerich is a fully integrated, self-managed, and self-administered real estate investment trust (REIT). As a leading owner, operator and developer of high-quality retail real estate in densely populated and attractive U.S. markets, Macerich's portfolio is concentrated in California, the Pacific Northwest, Phoenix/Scottsdale, and the Metro New York to Washington, D.C. corridor. Developing and managing properties that serve as community cornerstones, Macerich currently owns 45 million square feet of real estate consisting primarily of interests in 41 retail centers. Macerich is firmly dedicated to advancing environmental goals, social good and sound corporate governance. A recognized leader in sustainability, Macerich has achieved a #1 Global Real Estate Sustainability Benchmark (GRESB) ranking for the North American retail sector for ten consecutive years (2015-2024).
help-icon Live chat